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Abstract
Researchers are using the intraductal approach to advance breast cancer risk assessment,
prevention, diagnosis, and treatment. Procedures and technologies that can access and interrogate
the ductal-alveolar systems include nipple aspiration, ductal lavage and ductoscopy. Ductoscopic
papillectomy, ductoscopic margin evaluation, and intraductal therapy are considered promising
investigational and innovative treatments. These techniques are used to explore the biology of the
normal breast; collect and analyze breast fluid and cells to identify biomarkers that can be used in
breast cancer detection and risk assessment; and to identify new ways to find and administer
therapeutic and/or preventive agents to the breast tissue. This report summarizes the latest
research findings in these areas, presented at The 6th International Symposium on the Intraductal
Approach to Breast Cancer in 2009.
Introduction
The human breast is composed of multiple ductal lobular
systems that each open onto the surface of the nipple.
These ductal systems arborize into ductal trees with asso-
ciated lobules and are lined with epithelial cells, where
most breast cancers are thought to originate. The applica-
tion of suction to the nipple openings (nipple aspiration)
and ductal lavage are used to collect fluid and exfoliated
cells from the breast ducts. Many substances associated
with the growth, development, and tumorigeneses of the
breast have been detected in breast fluids. Cytological
techniques have shown that breast cancer-associated
abnormalities can be found in these cells [1-6]. In addi-
tion, the production and cytological properties of nipple
aspirate fluid are associated with breast cancer risk, with
long-term follow-up of women undergoing nipple aspira-
tion having shown that breast cancer risk is two to five
times greater in women diagnosed with cytologic atypia
than it is for women who do not yield fluid [7].
The first International Intraductal Symposium was held in
1999. A biennial event, the Symposium includes discus-
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sions and presentations on the anatomy and physiology
of the normal and diseased breast, advances in intraductal
technologies, findings from genetic, epigenetic, and pro-
teomic analyses of intraductal fluid, and the latest transla-
tional research on intraductal approaches to breast cancer
risk assessment, diagnoses, and treatment. The 6th Interna-
tional Symposium on the Intraductal Approach to Breast
Cancer, sponsored by the Dr. Susan Love Research Foun-
dation and held in Santa Monica, California, on 19–21
February 2009, was attended by more than 100 delegates
from 14 countries, including clinicians, epidemiologists,
pathologists, basic scientists, translational investigators,
and breast cancer advocates. The program included talks
by 34 invited speakers and 16 pilot grant applicants in ses-
sions that addressed the etiology of breast cancer; biomar-
kers of risk in nipple aspirate fluid and ductal lavage;
anatomy, ductoscopy, and breast imaging; and intraduc-
tal therapy. Delegates also had the opportunity to attend
demonstrations of ductoscopy, sonoductography, and
nipple aspirate fluid collection on live volunteers.
Minisymposium on a Novel Etiology for Breast 
Cancer: Inflammation
The first session's speakers discussed the role that inflam-
mation, nipple aspirate fluid and macrophages may play
in breast cancer development. Lisa Coussens (University
of California, San Francisco, USA) discussed her research
with an MMTV-PyMT mouse model of mammary carcino-
genesis that revealed a tumor-promoting role for TH2-
CD4 T effector cells. These novel findings suggest the
immune system modulates the early onset of cancer devel-
opment in specific organs, and confirmed epidemiologi-
cal studies showing that increased macrophage presence
correlates with higher tumor grade and decreased survival.
Eliminating the T effector cells did not regulate primary
disease, and also made it more likely that the cancer
would metastasize to the lung, behavior that appeared to
be regulated by macrophages. These findings could one
day translate into an immune signature that is an inde-
pendent predictor of recurrence risk, while identifying the
pro-tumor mechanisms could lead to new cancer treat-
ments.
Premalignant cell damage in the breast duct lining signals
a biochemical cascade that delivers inflammatory proteins
to the cell site. Chandice Covington (Texas Tech Univer-
sity Health Services Center, Lubbock, TX, USA) discussed
one of these proteins, C-Reactive. CRP is associated with
cancer risk, and has been shown to be present in increased
levels in serum in more advanced breast cancer. Dr. Cov-
ington data showed that CRP levels in nipple aspirate
fluid were associated with age at first pregnancy, gravidity,
wean-time from breast-feeding last baby, percentage body
fat, and body mass index and that CRP in NAF signifi-
cantly and positively related to breast cancer risk as pre-
dicted by the Gail model.
Several large epidemiological studies have shown that
non-steroidal anti-inflammatory drugs (NSAIDs) are
associated with lower breast cancer risk [8]. Patricia
Thompson (Arizona Cancer Center, Tucson, AZ, USA)
presented data from her phase Ib dose study investigating
the COX dependent and independent effect of sulindac, a
non-selective NSAID with COX-independent induction of
apoptosis, on NAF biomarkers. Sulindac also may affect
EGFR/HER2 downstream molecules. Thirty women with
increased breast cancer risk were randomized to 150 mg
or 300 mg of sulindac daily for 6 weeks. Nipple aspiration
was used to measure levels of sulindac in the breast fluid.
Sulindac and sulfide were detectable in 57.7% of NAF
samples with sulfone detectable in 11.6%. Serum levels
did not correlate with breast fluid levels. COX inhibition
in the breast was achieved at 150 mg sulindac, but the
higher dose was needed to exhibit activities via COX inde-
pendent pathways.
Taken together, these preliminary studies show that
NSAIDs in general and COX inhibitors, in particular,
could be promising agents in the prevention or early treat-
ment of breast cancer. More attention needs to be paid to
the pro- and anti-inflammatory nature of the microenvi-
ronment of the breast.
Biomarkers of risk in nipple aspirate fluid and 
ductal lavage
Intraductual approaches have the potential to offer new
methods of assessing an individual woman's breast cancer
risk. Cytology was the first method used to evaluate breast
fluid for risk assessment. However, it has been shown to
reveal a high degree of prognostically ambiguous atypia.
These results, in conjunction with recent technological
advancements, have resulted in a growing field of research
aimed at identifying biomarkers in breast fluid that could
be used for risk assessment as well as determining the best
techniques for finding these markers in NAF.
Viruses cause several major human cancers. Gertrude Bue-
hring (University of California, Berkeley, School of Public
Health, USA), a prior pilot grant recipient, discussed her
research exploring whether oncogenic viruses in NAF
mammary epithelial cells can serve as biomarkers to iden-
tify women at high risk for breast cancer. She is using in
situ polymerase chain reaction (PCR) to detect genomes
of bovine leukemia virus, Epstein-Barr virus, and human
papilloma virus. Studies have shown that all three of these
viruses are found more frequently in breast tissue of
women with breast cancer than they are in women with
no breast cancer history [9].BMC Proceedings 2009, 3(Suppl 5):I1 http://www.biomedcentral.com/1753-6561/3/S5/I1
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Massimo Tommasino (International Agency for Research
on Cancer, Lyon, France) presented data from his study
using PCR to evaluate HPV in ductal lavage fluid. His data
showed that DNA of alpha mucosa and beta cutaneous
HPV types are rarely present in the breast fluids of high-
risk women, suggesting that a direct role of HPV in breast
carcinogenesis is unlikely.
Paul J. van Diest (University Medical Center Utrect, The
Netherlands) discussed his ongoing prospective study,
which has high-risk women undergo annual standard
screening along with nipple aspiration. Expression of NAF
was enhanced in his study with the use of nasal oxytocin
spray. Quantitative multiplex methylation-specific PCR
(QM-MSP) is used to identify promoter methylation of a
selected set of tumor suppressor genes known to be
involved in breast carcinogenesis in the NAF. "In five to
ten years," said Dr. van Diest, "some of these high-risk
patients will either have an operation because they have
breast cancer or decide to have a prophylactic mastec-
tomy, which would permit us to compare methylation
data with what is found in surgical tissue to determine if
there is a correlation between the number of methylated
genes that are present and risk."
Proteomic profiling may have more value for risk assess-
ment than as a diagnostic screening tool. Savitri Krishna-
murthy (MD Anderson Cancer Center, Houston, TX, USA)
discussed her research that is using an array of techniques,
including ELISA, high-resolution proteomic analysis,
SELDI-TOF, and protein microarrays to identify protein
signatures in NAF that could be used for risk assessment.
The seven proteins her team is currently investigating
include insulin-like growth-factor binding protein-3,
basic fibroblast growth factor, CRP, erythropoietin, urok-
inase and prostaglandin E2.
Ercole Cavalieri, (Eppley Institute for Research in Cancer
and Allied Diseases, University of Nebraska Medical
Center, Omaha, NE, USA) discussed his research on DNA
adducts, which play a major role in cancer development.
Estrogen-purine DNA adducts are shed from cells and end
up in the blood and urine. His studies have shown that
high levels of estrogen-DNA adducts are associated with
breast cancer risk. He noted that "since the reaction of cat-
echol estrogen quinones with DNA is the first critical step
in the initiation of cancers, elimination of DNA adduct
formation should block the initiation and development
of cancer," this may be a new target for breast cancer pre-
vention and treatment.
Robert Chatterton (Feinberg School of Medicine, North-
western University, Chicago, IL, USA) presented data from
a study investigating the endocrine environment of the
breast. Forty-seven premenopausal and 40 postmenopau-
sal high-risk women underwent ductal lavage and NAF
collection and also provided a serum sample. Those at
high risk were offered tamoxifen as a chemopreventative
agent and a repeat ductal lavage 6 months later. The
results showed that NAF and ductal lavage fluid contain a
rich source of hormones and other markers of risk, but the
findings are too preliminary to draw any conclusions.
Ferdinando Mannello (University "Carlo Bo," Urbino,
Italy), a prior pilot grant recipient, presented an update on
his research study investigating the role oxidative stress
plays in the breast microenvironment and the function of
adhesion molecules in the breast cells of the ductal-lobu-
lar unit. He has published his findings on protein analyses
of NAF in healthy women versus breast cancer patients
[10].
Catharina Svanborg (Lund University, Sweden) is study-
ing HAMLET (human a-lactalbumin made lethal to tumor
cells), a protein-lipid complex that is found in human
milk, and that shows promise as a new anti-cancer agent.
HAMLET kills tumor cells and immature cells but spares
healthy differentiated leukocytes. HAMLET shows broad
anti-tumor activity, and Dr. Svanborg's studies have iden-
tified several death pathways activated by HAMLET in
tumor cells, including apoptosis, anoikis, and autophagy
[11].
Hypermethylated genes are promising powerful biomark-
ers of breast cancer detection and perhaps risk assessment.
Studies have shown that tumor suppressor gene (TSG)
methylation is identified more frequently in random peri-
areolar fine needle aspiration samples from women at
high risk for breast cancer than in women at low risk.
David Euhus (University of Texas Southwestern Medical
Center, Dallas, TX) investigated whether the finding that
would hold true for breast fluid samples obtained via duc-
tal lavage. For this study, 514 samples obtained from 150
women were assessed cytologically and by Quantitative
Multiplex Methylation-Specific PCR (QM-MSP) for meth-
ylation of cyclin D2, APC, HIN1, RASSF1A, and RAR-
beta2. Dr. Euhus reported that the study showed that TSG
methylation in ductal lavage samples did not predict
marked atypia, and that both methylation and marked
atypia were independently associated with highly cellular
samples, Gail model risk, and a personal history of breast
cancer, suggesting related, but independent, pathogenic
pathways in breast epithelium [12].
Mary Jo Fackler (Johns Hopkins University School of
Medicine, Baltimore, MD, USA) is also using QM-MSP to
identify potential biomarkers. Dr. Fackler presented find-
ings from a pilot study that explored the potential of using
ductoscopic washings along with QM-MSP to evaluate
spontaneous nipple discharge and that showed that QM-BMC Proceedings 2009, 3(Suppl 5):I1 http://www.biomedcentral.com/1753-6561/3/S5/I1
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MSP is 3-fold more sensitive than cytology in identifying
cancerous cells. She also discussed a prospective pilot
study of 54 postmenopausal women who were receiving
anastozole as their sole adjuvant therapy. Thirty-three of
the women had an optional contralateral biopsy at base-
line and at 6 months after starting treatment. A compari-
son of these biopsy samples showed significant decreases
in methylation for TWIST1, RASSF1A, and RARbeta. Both
findings suggest more prospective studies are necessary to
evaluate the relationship between changes in methylation
and breast cancer incidence.
Gerald Gui (Royal Marsden Hospital, London, UK) pre-
sented data from his study comparing measurements of
methylation-specific PCR in ductal lavage fluid, breast
cancer tissue, adjacent normal breast parenchyma, and
plasma in women with early breast cancer. The study
showed a positive correlation between tumor tissue and
ipsilateral ductal lavage in women with breast cancer (n =
24). Methylation was also significantly higher in tumor
and ipsilateral ductal lavage fluid when compared with
adjacent normal tissue and contralateral ductal lavage.
Bassem Haddad (Georgetown University, Washington,
DC, USA) discussed his research aimed at identifying a
panel of biomarkers that could improve the diagnostic
value of ductal fluid in detecting pre-malignant breast
lesions and early stages of breast cancer in high-risk
women. Edward Sauter (University of North Dakota
School of Medicine, Grand Forks, ND, USA) discussed his
use of two intraductal approaches, ductoscopy and nipple
aspiration, to assess response to both pharmacologic and
nutritional chemopreventive interventions.
Catherine Carpenter (University of California, Los Ange-
les, USA), a prior pilot grant recipient, provided an update
on her research investigating the impact of diet and exer-
cise on biomarkers in breast ductal fluid in overweight
postmenopausal women. To date, five previously seden-
tary overweight women have completed the study. Prelim-
inary midpoint data showed a major drop in leptin,
DHEA, and estrone in serum that was not mirrored in the
lavage fluid.
The Gail Risk model, which is widely used to assess breast
cancer risk, was developed based on data from Caucasian
women and has been found to be less accurate in assess-
ing risk in women of other ethnicities [13]. Lisa Bailey
(Carol Ann Read Breast Health Center, Alta Bates Summit
Medical Center, Oakland, CA, USA), a prior pilot grant
recipient, provided an update on her research exploring
the feasibility of an intraductal approach for risk assess-
ment in African American, Asian, and Hispanic women.
Atilla Soran (Magee-Womens Hospital, University of
Pittsburgh Medical Center, PA, USA), a prior pilot grant
recipient, presented preliminary research findings from
his study investigating anti-MUC1 and anti-cyclin B1 anti-
bodies in nipple aspirate fluid in breast cancer patients.
He suggested that more sensitive techniques for antibody
detection might be needed to identify the low antibody
levels in the premalignant lesions, which could boost the
usefulness of NAF as the source for this diagnostic assay.
These presentations demonstrated the different types of
strategies researchers are using to identify biomarkers
associated with genetic, epigenetic, and proteomic abnor-
malities in breast fluid. These reports add to growing body
of published studies that have found that biomarkers
appear to be more sensitive than cytologic atypia in pre-
dicting breast cancer risk. [14-22]
Anatomy, ductoscopy, and imaging of the breast
Intraductal approaches have been used to advance our
understanding of the anatomy of the breast. They have
provided evidence that the breast ducts do not form an
even, radial pattern, and shown us that there are both cen-
tral ducts that go directly back to the chest wall and
peripheral ducts that drape over this central group. This
knowledge of the anatomy of human breast will guide
future breast cancer research. Intraductal approaches are
also utilized in the intraoperative setting in patients with
both benign and malignant breast conditions to guide
treatment decisions. As James Going (University of Glas-
gow, Scotland, UK), a prior pilot grant recipient, under-
scored in his presentation, "Anatomy seems old-
fashioned, but a house without a good foundation is a
rickety structure and we need to understand that founda-
tion, no matter how good the biology."
Dr. Going's presented findings from his research investi-
gating what he calls "the paradox of nipple anatomy." As
he noted, 5–9 ostia can be observed in the lactating breast,
and a few of these ostia can be cannulated. Yet 20–30
ducts are observed when the nipple is transected raising
the question, "What are these ducts doing?" He found no
evidence for his previous two-duct-type hypothesis, but
did find evidence that appears to point to ostium sharing
– several ducts converging in a common opening in the
nipple.
Gerald Gui (Royal Marsden Hospital, London, UK)
reported findings from his study investigating the ana-
tomical association between fluid yielding ducts and
breast cancer location. This study of 40 patients undergo-
ing mastectomy for breast cancer, used ductal lavage fol-
lowed by infusion of the mastectomy specimens ex vivo
with a colored resin. It showed that the duct system of the
cancer affected segment was concordant to a fluid-yield-BMC Proceedings 2009, 3(Suppl 5):I1 http://www.biomedcentral.com/1753-6561/3/S5/I1
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ing duct in 58% of cases, a similar finding to previous
studies. Dr. Gui said this suggested that cytology studies
would likely be limited by duct accessibility whereas pro-
tein studies, which could demonstrate a field effect, would
not.
Sheldon Feldman (Columbia University New York City,
NY, USA) provided a history and overview of the field of
mammary ductoscopy. The ability to see ductal pathology
and monitor response to therapy in real time along with
technological improvements, including better visualiza-
tion and an interventional approach, are moving the field
forward. Current challenges include the absence of an
established CPT code and a lack of data from clinical trials
evaluating the efficacy and clinical role of ductoscopy or
randomized trials evaluating whether more cancers are
found with ductoscopy. Even so, said Dr. Feldman, "We
are on the threshold of the future."
Fatih Balci (Ankara State Hospital, Ankara, Turkey) pre-
sented images and data from his study evaluating the ther-
apeutic value of endoscopic papillectomy in patients with
pathologic nipple discharge (PND). Breast ductoscopy
was performed on 178 of 213 patients with PND enrolled
in the study. All visualized papillomas were removed
endoscopically with a scope with a grasping basket. Dr.
Balci reported that they identified 34 papillomas and 5
cases of DCIS, and that there was a 100% correlation
between ductoscopy findings and histopathology. These
findings, said Dr. Balci, confirm that ductoscopic papillec-
tomy "is a safe and easy procedure to remove intraductal
papillomas from the breast that avoids unnecessary resec-
tion of breast tissue"[23].
William Dooley (University of Oklahoma, Oklahoma
City, OK, USA) discussed current techniques and uses for
ductoscopy. In his clinical practice, Dr. Dooley routinely
uses ductoscopy to manage early invasive cancer. As a
result, he said, he has a low annual hazard rate for ipsilat-
eral breast cancer recurrence. In the discussion that fol-
lowed, Dr. Dooley noted that surgeons rely on radiation
to improve local control, but that ductoscopy could do
the same. "If we can get good enough at doing endoscop-
ically directed lumpectomy," he said, "we would not need
to perform radiation unless there was lymphovascular
invasion." One essential area needed to advance the field
of ductoscopy will be carefully planned prospective multi-
center studies to address the sensitivity, specificity, false
negative and false positive rates of ductoscopy in accu-
rately identifying cancerous versus non-cancerous tissue.
Wai-ka Hung (Kwong Hospital, Kowloon, Hong Kong)
discussed the role of mammary ductoscopy in breast sur-
gery, also noting that for the field to move forward good
endoscopic-pathologic correlation was necessary. This, in
turn, could spare women unnecessary surgery, as it would
allow for therapeutic mammary ductoscopy and removal
or ablation of a papilloma. In addition, if it could be
determined that there was no ductal involvement in the
areola, it might also be used to better select appropriate
candidates for for nipple-sparing mastectomy.
Debra Strick (University of California, Los Angeles, USA),
a prior pilot grant recipient, presented findings from her
research on intraductal micromagnetic resonance imaging
and spectroscopy. Dr. Strick developed an intraductal
radiofrequency microcoil that can reduce the volume of
diseased tissue to a cubic-centimeter, allowing MRI spec-
troscopy, which could distinguish between benign and
malignant tissue, and therefore be used for early diagno-
sis. This microcoil could potentially be used with ductos-
copy and conventional MRI to reduce false-positives or for
an MRI-guided biopsy.
Intraductal therapy: background, current and 
future
The session on intraductal therapy highlighted studies
investigating preclinical testing and early phase human
clinical trials.
Dixie Mills (Dr. Susan Love Research Foundation, Santa
Monica, CA, USA) presented data from a study exploring
the physiology of the resting, or non-lactating, breast. A
total of 14 women underwent blood collection, nipple
aspiration, and ductal lavage five times over 12 hours.
After baseline testing, subjects were given 200 mg of caf-
feine (NoDoz) and 200 mg of cimetidine (Tagamet). Pre-
vious studies have shown that in lactating women caffeine
passively diffuses into milk rapidly and reflects serum lev-
els. This study found that in the resting breast, caffeine lev-
els peaked at 6 hours or later. Cimetidine has previously
been found to be concentrated in the milk of lactating
women, but was not detected in the ductal fluid obtained
from the resting breast. These findings reinforce the need
for more studies on the resting breast as its properties are
clearly different than the lactating breast.
Saraswati Sukumar (The Sidney Kimmel Comprehensive
Cancer Center, Johns Hopkins University, Baltimore, MD,
USA) presented new data from her preclinical studies with
pegylated liposomal doxorubicin (PLD) in rat and mouse
models of breast cancer. Dr. Sukumar reported that in
addition to preventing tumor formation for three months
or more, PLD appeared to stunt the growth of the mam-
mary glands in mice. Following up on this finding, she
looked at the response of the treated mammary gland to a
new pregnancy. She reported that that pups were unable
to get sufficient milk from the treated duct, suggesting a
compromised response in the mammary gland to preg-
nancy hormones. In addition, pregnancy did not increaseBMC Proceedings 2009, 3(Suppl 5):I1 http://www.biomedcentral.com/1753-6561/3/S5/I1
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the incidence of tumors in PLD treated mice. She also
noted that their studies have found that mice receiving
intraductal treatment have fewer stem cells than other
mice, which has resulted in a new line of investigation
[24].
Moving into the clinic setting, Vered Stearns (Johns Hop-
kins School of Medicine, Baltimore, MD, USA) presented
data from a phase I feasibility study of PLD in women
awaiting mastectomy. Participants underwent nipple aspi-
ration and ductal cannulation using a dose escalation
scheme. Blue dye was injected into the treated duct just
prior to mastectomy and tissue was obtained for pharma-
cokinetic and biomarker analysis. Dr. Stearns reported
that doxil was present in the region at both the 5 mg and
10 mg dose, evidence that it can leave the duct. No
changes were seen in the stroma surrounding the ducts,
however a dose-dependent effect was seen in plasma and
in breast tissue. Noting that there is no data on how IV
doxil affects breast tissue, Dr. Stearns said her next study
would compare the breast tissue of women who receive IV
doxil prior to surgery with that of women receiving intra-
ductal doxil.
Susan Love (Dr. Susan Love Research Foundation, Santa
Monica, CA, USA) presented data from a Phase I feasibil-
ity study conducted in Beijing, China. One of two drugs,
PLD or carboplatin, were used intraductally 2–7 days
prior to mastectomy, at 3 dose levels, with the highest
dose approximating the clinical intravenous dose. Dr.
Love reported that PLD stayed in the duct longer and
showed a lower serum dosage. At the highest doses,
women receiving PLD reported tenderness and erethyma,
whereas the highest doses of carboplatin resulted in mild
nausea and vomiting, a sign that the drug had gotten into
the bloodstream. Dr. Love also reported that pathological
examination showed the drugs were widely distributed
through the ductal systems reaching the terminal duct
lobular units. In conclusion, said Dr. Love, this shows us
that this approach is feasible and safe.
Jianyu Rao (David Geffen School of Medicine, University
of California, Los Angeles, USA) described the histopatho-
logical changes observed in the study Dr. Love presented.
The pathology was not performed to study the tumor but
to assess ductal epithelial cell changes and inflammatory
reaction seen in ducts and surrounding fibroadipose tis-
sue in association with duct treatment. Dr. Rao reported
that carboplatin resulted in a dose-response increase of
both in inflammation and ductal epithelial cell changes.
In contrast, PLD resulted in no severe inflammatory
changes in any dose group, but there was a significant
increase of epithelial response. Dr. Rao said this suggests
that short-term intraductal treatment may induce some
degree of epithelial changes and some inflammatory
response, while the long-term effect remains to be deter-
mined.
Ellen Mahoney (St. Joseph Hospital, Eureka, CA, USA)
presented data from her pilot preoperative study testing
the effects of PLD delivered through the affected duct of
30 women with DCIS diagnosed by core needle biopsy
awaiting surgery. To date, six patients have undergone
treatment. In those who were treated successfully with
PLD, the pathology has revealed reactive and reparative
changes to the duct. If this proves effective, said Dr.
Mahoney, we could develop "a chemical mastectomy for
post-breastfeeding women that would eradicate the stem
cells and epithelial cells inside the breast duct, thus elim-
inating the possibility for breast cancer to occur."
Taken together, the intraductal approach for potential pre-
vention and therapy of breast cancer has been born and is
growing as more researchers begin to study and answer
the critical questions needed to advance this exciting
emerging field.
Pilot grants
The Dr. Susan Love Research Foundation utilizes a unique
grant review mechanism to distribute pilot grants at the
Symposium. Applicants submit one-page abstracts and
responsive proposals are selected for presentation at the
meeting. A multidisciplinary peer review committee, com-
prised of basic scientists, breast cancer activists, and phy-
sicians, evaluates both the abstracts and the presentations.
At the Symposium, 16 researchers presented proposals. At
the close of the Symposium, the Foundation announced
that it would be providing $84,000 to support 8 innova-
tive research projects utilizing the intraductal approach.
The 2009 recipients were: Robert Chatterton, PhD, and
Seema Khan, PhD (Northwestern University), 'Investiga-
tion of factors regulating estrogen uptake and retention by
the breast'; Hong Ling, MD (Cancer Institute, Fudan Uni-
versity), 'Comparison of PH value in nipple aspiration
fluid from ductal carcinoma with or without calcification';
Ferdinando Mannello, PhD, and Gaetana Tonti, PhD
(University of Urbino 'Carlo Bo'), 'Iron-driven inflamma-
tion in the breast microenvironment: assessment of iron-
overload in breast cancer development'; Atilla Soran, MD
(University of Pittsburgh Medical Center), 'Autofloures-
cence ductoscopy for the early detection of breast cancer';
Barbara Urban, MD, and Lorriaine Tafra, MD (Anne Arun-
del Breast Center), 'Pilot study to identify breast cancer
protein biomarkers in nipple aspirate fluid'; Ameae
Walker, PhD (University of California, Riverside), 'A pro-
lactin binding compound in breast ductal fluids';
Daniel Wreschner, MD (Tel-Aviv University), 'Mono-
clonal antibodies and peptides targeting the MUC1 alpha/BMC Proceedings 2009, 3(Suppl 5):I1 http://www.biomedcentral.com/1753-6561/3/S5/I1
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beta junction of the ablation of human cancer cells via the
intraductal approach'; Gang Zeng, PhD (University of Cal-
ifornia, Los Angeles), 'A multiplex approach for detecting
antibodies in the nipple fluid of breast cancer patients'.
Conclusion
The 6th  International Symposium on the Intraductal
Approach to Breast Cancer highlighted the advances that
have made in intraductal research and the potential the
intraductal approach has to change clinical practice. Dele-
gates in attendance expressed an interest in designing col-
laborative studies that can provide more data on the
effectiveness of ductoscopy and identify new biomarkers
in breast fluid. An update on these projects, along with
findings from this year's pilot grant projects, will be pre-
sented in 2011 at the 7th International Symposium on the
Intraductal Approach to Breast Cancer.
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